Aurobindo acquires 7 oncology drugs from spectrum for $300 million
Nasdaq-listed Spectrum Pharmaceuticals has carved out its commercial business inclusive of seven marketed oncology injectable products, intellectual property and commercial infrastructure.
Nasdaq-listed Spectrum Pharmaceuticals has carved out its commercial business inclusive of seven marketed oncology injectable products, intellectual property and commercial infrastructure.
No comments:
Post a Comment
Thank you